Examples of 'blinatumomab' in a sentence
Meaning of "blinatumomab"
Blinatumomab is a noun referring to a specific type of medication, often used in medical contexts. It is likely a technical or scientific term related to healthcare or pharmaceuticals
Show more definitions
- A particular fusion protein with anticancer properties.
How to use "blinatumomab" in a sentence
Basic
Advanced
blinatumomab
Blincyto contains the active substance blinatumomab.
The metabolic pathway of blinatumomab has not been characterised.
Blinatumomab is presently in clinical trials.
There are no data from the use of blinatumomab in pregnant women.
Blinatumomab has major influence on the ability to drive and use machines.
The active substance is blinatumomab.
It is unknown whether blinatumomab or metabolites are excreted in human milk.
No studies have been conducted to evaluate the effects of blinatumomab on fertility.
No formal pharmacokinetic studies of blinatumomab have been conducted in patients with hepatic impairment.
Reproductive toxicity studies have not been conducted with blinatumomab.
No formal pharmacokinetic studies of blinatumomab have been conducted in patients with renal impairment.
Blinatumomab consists of four immunoglobulin variable domains assembled into a single polypeptide chain.
Blincyto contains the active substance blinatumomab and is used on its own.
Blinatumomab is produced in Chinese hamster ovary cells by recombinant DNA technology.
A population pharmacokinetic analysis was performed to evaluate the effects of demographic characteristics on blinatumomab pharmacokinetics.
See also
Negligible amounts of blinatumomab were excreted in the urine at the tested clinical doses.
The active ingredient in BLINCYTO is blinatumomab.
Blinatumomab should come with a Medication Guide.
Bispecific T cell engager antibodies such as blinatumomab.
Anti - blinatumomab antibody formation might affect pharmacokinetics of blinatumomab.
There is very limited experience with blinatumomab in adults weighing less than 45 kg.
Blinatumomab is given as a continuous IV infusion for 28 consecutive days per cycle.
The median time from initiation of blinatumomab to onset of a neurologic event was 9 days.
Blinatumomab is usually given every day for 4 weeks followed by a 2-week treatment free-interval.
Specifically included among such BiTEs are that target CD19, such as blinatumomab.
Blinatumomab specifically targets the CD19 antigen present on B cells.
BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion blinatumomab.
Reconstitution with water for injections results in a final blinatumomab concentration of 12.5 micrograms / mL.
After reconstitution with water for injections each vial contains 12.5 micrograms / mL of blinatumomab.
The majority of patients who respond to blinatumomab achieve a response after 1 cycle ( see section 5.1 ).
The pharmacokinetics of blinatumomab appear linear over a dose range from 5 to 30 mcg/m2/day in paediatric patients.
